Alvotech and Advanz Pharma Expand Biosimilar Partnership in Europe

Alvotech ( (ALVO) ) just unveiled an update.

On May 28, 2025, Alvotech announced an extension of its partnership with Advanz Pharma to commercialize three additional biosimilar candidates in Europe. This agreement, which includes biosimilars to Ilaris® and Kesimpta®, highlights Alvotech’s expanding biosimilar pipeline and strategic growth in the European market. The partnership, which involves development and commercial milestones totaling up to $180 million, positions both companies to enhance access to specialty and rare disease medicines, potentially impacting the $13.8 billion addressable market.

The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.

Alvotech’s stock is rated moderately due to strong revenue growth and improved profitability offset by financial instability and cash flow concerns. Positive technical indicators and promising earnings guidance enhance the outlook, but valuation is moderate, and competitive pressures remain a risk.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines. The company aims to be a leader in the biosimilar space, offering high-quality, cost-effective products. Alvotech has a diverse pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and has established strategic partnerships worldwide to enhance its market reach.

Average Trading Volume: 172,030

Technical Sentiment Signal: Sell

Current Market Cap: $3.42B

For a thorough assessment of ALVO stock, go to TipRanks’ Stock Analysis page.